RHHVF
July 25, 2024 - AI Summary
Undervalued by 138% based on the discounted cash flow analysis.
Market cap | $304.19 Billion |
---|---|
Enterprise Value | $334.08 Billion |
Dividend Yield | $10.97 (3.38%) |
Earnings per Share | $10.39 |
Beta | 0.18 |
Outstanding Shares | 802,817,000 |
Return on Equity | - |
---|---|
Return on Assets | - |
Return on Invested Capital | - |
P/E Ratio | 40.22 |
---|---|
PEG | 218.51 |
Price to Sales | 2.37 |
Price to Book Ratio | 8.78 |
Enterprise Value to Revenue | 2.73 |
Enterprise Value to EBIT | 11.02 |
Enterprise Value to Net Income | 16 |
Total Debt to Enterprise | 0.11 |
Debt to Equity | 1.31 |
No data
No data
Roche Holding AG operates as a research healthcare company. It operates through the following segments: Diagnostics and Pharmaceuticals. The Pharmaceutical segment refers to development of medicines in the field of oncology, immunology, ...